register free | resend password


DGAP-News: Novavax Acquires Isconova; Extends Public Tender Offer Period for Remaining Isconova Shareholders

ID: 1250214
recent pressrelease next pressrelease

(businesspress24) - Novavax, Inc.

31.07.2013 08:00
---------------------------------------------------------------------------

ROCKVILLE, Md., 2013-07-31 08:00 CEST (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) announced today the number of shares and warrants
tendered to it in its recommended public offer to acquire all issued and
outstanding shares and warrants (warrants series 2005-I and 2005-II) of
Isconova AB ('Isconova'), which was first communicated on June 4, 2013, (the
'Offer').

As of July 30, 2013, approximately 12,152,077 shares and all warrants issued by
Isconova, corresponding to approximately 97.4 per cent of the shares and 100
per cent of the warrants issued by Isconova, respectively, have been validly
tendered and not properly withdrawn. Novavax did not hold any shares or
warrants in Isconova prior to the announcement of the Offer and has not
acquired any shares or warrants in Isconova outside the Offer.

Given that greater than 90 per cent of the total number of shares on a fully
diluted basis (including all issued warrants and stock options) have been
validly tendered and not properly withdrawn, and that all other terms of the
Offer have been fulfilled, Novavax declares the Offer unconditional and will
complete the Offer and accept the securities tendered on July 30, 2013.
Settlement is expected to begin on or before August 9, 2013.

In order to give holders of shares in Isconova additional time to accept the
Offer, Novavax hereby extends the acceptance period in the Offer, to expire on
24:00, Central European Summer Time (6:00 pm Eastern Time) on August 20, 2013.
Settlement for shares tendered during the extended acceptance period is
expected to begin on or before August 27, 2013.

As Novavax holds more than 90 per cent of shares in Isconova, Novavax intends
to initiate compulsory acquisition proceedings to acquire all remaining shares


in Isconova in accordance with the Swedish Company's Act and act to have the
shares in Isconova de-listed from NASDAQ OMX First North Premier.

The Swedish prospectus, together with the United States (U.S.) prospectus
included as part of the registration statement filed by Novavax to register the
shares to be issued in the Offer, are available at Novavax' webpage
(www.novavax.com), at Pareto Ohman AB's webpage (www.paretosec.com), and at
Isconova's webpage (www.isconova.com). Shareholders in Isconova considering the
Offer should read the information in these documents because they will contain
important information regarding the Offer. The Swedish prospectus, the U.S.
prospectus, the information brochure and acceptance forms can also be ordered
from Pareto Ohman AB by phone (+ 46 (0) 8 402 51 32). Shareholders in Isconova
considering the Offer may obtain copies of all documents filed with the U.S.
Securities and Exchange Commission (SEC) regarding the Offer, free of charge,
at the SEC's website (www.sec.gov).

This information was made public on July 31, 2013, at 08:00 CET.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating vaccines to address a broad range of infectious diseases worldwide.
Using innovative recombinant nanoparticle technology, as well as new and
efficient manufacturing approaches, the company produces vaccine candidates to
combat diseases, with the goal of allowing countries to better prepare for and
more effectivelyrespond to rapidly spreading infections. Novavax is committed
to using its technology platform to create geographic-specific vaccine
solutions and is therefore involved in several international partnerships,
including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences
of Korea and PATH. Together, these organizations support Novavax' worldwide
commercialization strategy and have the global reach to create real and lasting
change in the biopharmaceutical field. Additional information about Novavax is
available on the company's website, www.novavax.com.


CONTACT: John A. Herrmann
VP, General Counsel and Secretary
Novavax, Inc.
240-268-2000
News Source: NASDAQ OMX



31.07.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Novavax, Inc.


United States
Phone:
Fax:
E-mail:
Internet:
WKN:

End of Announcement DGAP News-Service

---------------------------------------------------------------------------



Keywords (optional):

novavax-acquires-isconova, extends-public-tender-offer-period-for-remaining-isconova-shareholders,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: EquityStory
print pressrelease  send to a friend  

Date: 07/31/2013 - 08:00
Language: English
News-ID 1250214
Character count: 0
Kontakt-Informationen:
Firma: Novavax, Inc.
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt:
Telefon:

Comments:



Number of hits: 201

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 66


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.